Guide cuts through anticoagulant 'hype'

Patients who are well controlled on warfarin are unlikely to benefit from switching to the novel anticoagulants, according to an educational campaign launching Tuesday.

The NPS program seeks to cut through the ‘hype' around new agents such as dabigatran (Pradaxa) and provide a practical guide to which patients will actually benefit from switching off warfarin.

It includes an online decision support tool for starting patients on the new agents as well as